Grapefruit USA Inc (GPFT): Your right my mistake your money went t...

mr_sano · 2024-03-22T17:03:38.5500000Z

Your right my mistake your money went to financing the Y law practice.

Play Episode

7min

Proactive - Interviews for investors

TNR Gold chair welcomes progress at McEwen Copper's Los Azules copper project in Argentina

TNR Gold Corp (TSX-V:TNR, OTC:TRRXF) executive chairman Kirill Klip talked with Proactive's Stephen Gunnion about the company’s latest developments, including a key milestone in its transition to a cash-flow-generating royalty business. Klip highlighted that TNR Gold holds royalties on significant projects, including the Los Azules Copper project and the Mariana Lithium project in Argentina. With Los Azules now applying for Argentina's incentive regime for large investments, he explained that the project could see substantial tax reductions, making it easier to attract the $2.7 billion investment required for construction. Discussing Argentina’s economic reforms under President Javier Milei, Klip noted that the country's policies are encouraging large-scale investment in the mining sector. He also pointed to the environmental permit secured for Los Azules, bringing it closer to a construction decision, with a feasibility study expected in the first half of the year. Klip also shared insights from Fundamental Research Corporation’s latest analysis, which increased its price target for TNR Gold from $0.24 to $0.28, underscoring the company's transition from a project generator to a cash-flow-generating royalty company. Watch the full interview for more insights into TNR Gold’s latest developments. For more interviews like this, subscribe to Proactive’s YouTube channel, give this video a like, and turn on notifications for future updates! #TNRGold #MiningInvesting #LosAzules #CopperMining #LithiumInvesting #MiningStocks #ArgentinaMining #RoyaltyCompany #StockMarket #JavierMilei

Proactive - Interviews for investors

Millennial Potash advances Banio Project with resource potential and government support

Millennial Potash Corp (TSX-V:MLP, OTCQB:MLPNF) is advancing its Banio Potash Project in Gabon, leveraging extensive historical data and significant resource potential. Speaking at the PDAC conference in Toronto, Chairman Farhad Abasov shared key updates with Proactive’s Angela Harmantas, highlighting the project’s economic viability, strategic location, and government support. A recently completed economic assessment confirmed a 1.7 billion tonne indicated and inferred resource estimate, reinforcing the project’s scale and cost competitiveness. Abasov emphasized Banio’s proximity to major agricultural markets such as Brazil, India, China, and Africa, ensuring strong demand for its potash production. Gabon’s mining reforms have strengthened the project’s outlook, with the government actively supporting the Banio Project. Abasov noted a recent visit from the country’s president, signaling confidence in its economic and strategic value. Key milestones for 2024 include ongoing environmental studies, a second phase of drilling to expand the resource base, and the initiation of a feasibility study, which will run parallel to environmental assessments and is expected to conclude by early 2025. With strong backing, a large resource base, and a clear path to development, Millennial Potash is positioning itself as a major future supplier of potash, supporting global food security while contributing to Gabon’s economic growth. #tsxv #mlp #otcqb #mlpnf MillennialPotash #PotashMining #GabonMining #BanioProject #MiningInvestment #NaturalResources #MiningStocks #Commodities #SustainableMining #ProactiveInvestors

Proactive - Interviews for investors

Frontier IP investee GraphEnergyTech discusses solar panel collaboration

GraphEnergyTech CEO Dr Thomas Baumeler discussed a collaboration with the Taiwan Perovskite Solar Corporation, Taiwan’s prestigious Industrial Technology Research Institute and the University of Cambridge. The project is supported by an Innovate UK grant worth nearly £900,000. Known as GETPSC (Graphene Electrode Technology for Perovskite Solar Cells), Baumeler explained that current solar cells rely on expensive silver electrodes, which degrade when in contact with Perovskite Solar Cells. GraphEnergyTech, a Frontier IP Group PLC (AIM:FIPP) portfolio company, aims to replace these with graphene-based electrodes, offering a more stable and cost-effective alternative. "Graphene is one of the most interesting materials out there," he said, highlighting its durability and lower cost compared to silver. Perovskite Solar Cells are considered the next major advancement in photovoltaics due to their efficiency and simpler manufacturing process. However, industrial-scale adoption has been hindered by the lack of a viable nonmetallic electrode—something GraphEnergyTech aims to solve. Baumeler also noted that GraphEnergyTech is working on replacing silver electrodes in traditional silicon-based solar cells while exploring applications for its conductive carbon-based technology in batteries, supercapacitors, and electronics. For more insights into renewable energy innovations, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future updates. #GraphEnergyTech #SolarEnergy #GrapheneTech #PerovskiteSolar #RenewableEnergy #CleanEnergy #TechInnovation #SolarCells #GreenTechnology #EnergyStorage

Proactive - Interviews for investors

Daniel Tillett on Race Oncology’s drug advancements

Race Oncology Ltd CEO and managing director Daniel Tillett talked with Proactive about the company’s development of a reformulated cancer drug aimed at improving chemotherapy treatment. Tillett discussed the challenges of chemotherapy, including severe side effects, and how Race Oncology is working to minimise these risks while enhancing treatment effectiveness. He explained that the company has taken an older, previously approved drug and developed a new formulation that improves its delivery while protecting patients from heart-related side effects. This new approach, which involves combining the reformulated drug with anthracyclines, aims to enhance cancer treatment while reducing long-term health risks for patients. Tillett highlighted the significant market potential for the company’s drug, given that anthracyclines remain a cornerstone of cancer treatment. The company is now advancing into clinical trials, with results expected to provide key insights into the drug’s effectiveness in humans. Watch the full interview to learn more about Race Oncology’s latest advancements. Don’t forget to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications for more updates on cutting-edge biotech developments. #RaceOncology #CancerTreatment #Biotech #Chemotherapy #Pharmaceuticals #DrugDevelopment #ClinicalTrials #OncologyResearch #Investing #CancerResearch #Cardioprotection

Followers	31
Posts	7814
Boards Moderated	0
Alias Born	01/24/2007

Volume:	51,501
Day Range:	0.00055 - 0.00055
Bid:	0.0005
Ask:	0.0007
Last Trade Time:	2:34:28 PM EDT
Total Trades:	3

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

GPFT Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free